Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;14(2):153-159.
doi: 10.1038/nmeth.4104. Epub 2016 Dec 19.

In vivo high-throughput profiling of CRISPR-Cpf1 activity

Affiliations

In vivo high-throughput profiling of CRISPR-Cpf1 activity

Hui K Kim et al. Nat Methods. 2017 Feb.

Abstract

CRISPR from Prevotella and Francisella 1 (Cpf1) is an effector endonuclease of the class 2 CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRISPR-associated proteins) gene editing system. We developed a method for evaluating Cpf1 activity, based on target sequence composition in mammalian cells, in a high-throughput manner. A library of >11,000 target sequence and guide RNA pairs was delivered into human cells using lentiviral vectors. Subsequent delivery of Cpf1 into this cell library induced insertions and deletions (indels) at the integrated synthetic target sequences, which allowed en masse evaluation of Cpf1 activity by using deep sequencing. With this approach, we determined protospacer-adjacent motif sequences of two Cpf1 nucleases, one from Acidaminococcus sp. BV3L6 (hereafter referred to as AsCpf1) and the other from Lachnospiraceae bacterium ND2006 (hereafter referred to as LbCpf1). We also defined target-sequence-dependent activity profiles of AsCpf1, which enabled the development of a web tool that predicts the indel frequencies for given target sequences (http://big.hanyang.ac.kr/cindel). Both the Cpf1 characterization profile and the in vivo high-throughput evaluation method will greatly facilitate Cpf1-based genome editing.

PubMed Disclaimer

References

    1. Cytogenet Genome Res. 2004;106(1):28-32 - PubMed
    1. PLoS One. 2011;6(12):e29101 - PubMed
    1. Nat Biotechnol. 2014 Mar;32(3):279-84 - PubMed
    1. J Stat Softw. 2010;33(1):1-22 - PubMed
    1. Nat Commun. 2014 Feb 26;5:3378 - PubMed

MeSH terms

Substances